Hualan Biological Vaccine Inc. News

Hualan Vaccine (301207) Interim Report Review: Performance is under pressure and waiting for influenza vaccine sales to pick up

中原證券Sep 13 18:52

Hualan Vaccine (301207): Continued lead in issuing batches pending release of influenza vaccine

Aug 30 11:11

Hualan Vaccine (301207): The first half of the year showed normal results, awaiting sales in the second half of the year

Aug 30 00:00

Hualan Vaccine (301207): Increased willingness to get vaccinated against influenza continues to increase new profit growth points

Apr 8 16:56

Hualan Vaccine (301207): Performance is in line with expectations, and there is a marked recovery in influenza vaccine doses

Apr 1 16:31

Hualan Vaccine (301207): Multiple factors help the company increase its influenza vaccine net profit YOY +66% in 2023

Apr 1 00:00

Hualan Vaccine (301207): Demand for influenza vaccines has recovered and new product releases are expected

Mar 31 00:00

Hualan Vaccine (301207): Net profit from influenza vaccine doses is expected to increase by 44% to 83% in 2023

Jan 24 18:22

Hualan Vaccine (301207): The performance is in line with expectations and continues to be optimistic about the 2024 influenza vaccine performance

Jan 23 00:00

Hualan Vaccine (301207): Performance meets expectations and enters peak vaccination season

Oct 30, 2023 00:00

Hualan Vaccine (301207) Company Review: It is recommended to continue to pay attention to marginal changes in influenza A vaccine as scheduled

Oct 28, 2023 00:00

Hualan Vaccine (301207): Leading influenza vaccine performance is expected to return to positive growth

Oct 25, 2023 07:52

Hualan Vaccine (301207): Seeing the Japanese influenza vaccine industry leader ready to go

Oct 17, 2023 14:12

Hualan Vaccine (301207): Leading domestic influenza vaccine manufacturer, quadrivalent influenza vaccine creates Hualan's strength

Oct 13, 2023 15:52

Hualan Vaccine (301207): Delays in batch issuance led to a decline in performance and optimism about influenza vaccine sales volume in the second half of the year

華鑫證券Aug 31, 2023 00:00

Hualan Vaccine (301207): Delays in batch issuance affect performance release pace, sales repayment situation improved dramatically

光大證券Aug 24, 2023 13:42

Hualan Vaccine (301207): The pace of batch issuance disrupts demand throughout the year and is expected to recover

華泰證券Aug 23, 2023 00:00

Hualan Vaccine (301207): Influenza vaccine sales increase, demand is expected to rise throughout the year

華泰證券Apr 23, 2023 00:00

Hualan Vaccine (301207): 1Q influenza vaccine sales increase demand throughout the year or recover

華泰證券Apr 10, 2023 00:00

Hualan Vaccine (301207): Sales disrupted by the pandemic are expected to rise sharply in 2023

華泰證券Mar 31, 2023 00:00